The levels of IL‐1β, IL‐6, IL‐17, and IFN‐α decreased after treatment in the TACE+LEN + PD‐1 group, and treatment with PD‐1 inhibitor in the TACE+LEN + PD‐1 group was superior to that in the TACE+LEN group in reducing the level of these tumor‐related factors, which may be attributed to the blocking effect of the PD‐1 inhibitor immune pathway (Tables 3 and 4). Here, IL17A is linked to neoplasm.